TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
RAPT Therapeutics ( (RAPT) ) has issued an update.
On November 24, 2025, RAPT Therapeutics announced that Chief Medical Officer Dr. William Ho will leave the company on December 31, 2025. Dr. Ho will receive severance benefits and healthcare coverage, and will continue as a strategic consultant with the company until December 31, 2026, allowing him to retain equity award vesting rights.
The most recent analyst rating on (RAPT) stock is a Buy with a $57.00 price target. To see the full list of analyst forecasts on RAPT Therapeutics stock, see the RAPT Stock Forecast page.
Spark’s Take on RAPT Stock
According to Spark, TipRanks’ AI Analyst, RAPT is a Underperform.
RAPT Therapeutics’ overall stock score reflects significant challenges, primarily due to its inability to generate revenue and consistent operational losses. The strong equity position in the balance sheet is a positive, but technical indicators suggest a continued downward trend. The negative valuation metrics further highlight the risks associated with the stock.
To see Spark’s full report on RAPT stock, click here.
More about RAPT Therapeutics
RAPT Therapeutics, Inc. operates in the biotechnology industry, focusing on the development of oral small molecule therapies for oncology and inflammatory diseases.
Average Trading Volume: 434,345
Technical Sentiment Signal: Buy
Current Market Cap: $921.7M
Find detailed analytics on RAPT stock on TipRanks’ Stock Analysis page.